This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan;12(1):3-5.

doi: 10.1016/S1473-3099(11)70277-8. Epub 2011 Oct 18.

Elvitegravir: a once daily alternative to raltegravir

Belete Ayele Desimmie¹, Rik Schrijvers, Zeger Debyser

Affiliations

PMID: 22015078
DOI: 10.1016/S1473-3099(11)70277-8

Comment

Elvitegravir: a once daily alternative to raltegravir

Belete Ayele Desimmie et al. Lancet Infect Dis. 2012 Jan.

. 2012 Jan;12(1):3-5.

doi: 10.1016/S1473-3099(11)70277-8. Epub 2011 Oct 18.

Authors

Belete Ayele Desimmie¹, Rik Schrijvers, Zeger Debyser

Affiliation

¹ Molecular Medicine K U Leuven, 3000 Leuven, Flanders, Belgium.

PMID: 22015078
DOI: 10.1016/S1473-3099(11)70277-8

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team. Molina JM, et al. Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18. Lancet Infect Dis. 2012. PMID: 22015077 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information